TO STUDY OF EFFECT OF AMRITA GUGGULU, RASNASAPTAKA KWATHA AND RUKSHA SWEDA IN THE TREATMENT OF AMAVATA( RHEUMATOID ARTHRITIS)."

"EVALUATION OF THE EFFICACY OF AMRITA GUGGULU, RASNASAPTAKA KWATHA AND RUKSHA SWEDA IN THE MANAGEMENT OF AMAVATA( RHEUMATOID ARTHRITIS)."

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016096

Enrollment

Registered

2018-10-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: GROUP A-AMRITA GUGGULU and RASNASAPTAKA KWATH. : 15 clinically diagnosed and registered patients of â??Amavataâ?? will be treated by â??Amrita gugguluâ?? 2 Tab (each Tab 500mg) three t

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to sign consent form for the clinical trial. 2.Patients between the age group of 20 to 60 years, irrespective of sex and socio-economic status. 3.Patients having signs and symptoms of â??Amavata rogaâ??(Rheumatoid Arthritis). 4.Patients with chronicity of less than 5 years.

Exclusion criteria

Exclusion criteria: 1.Patients having severe joint deformities. 2.Patients suffering from paralysis. 3.Patients having any type of arthopathy such as Neoplasm of spine, Gout, Ankylosing spondylosis, Traumatic arthritis and Pyogenic osteomylitis etc. 4.Patients having associated Cardiac disease, Tuberculosis, Diabetes mellitus, Malignant Hypertension, Renal Function Impairment, Hypothyroidism, RHD etc. 5.Patients with extremely reduced joint space. 6.Pregnant women and lactating mother.

Design outcomes

Primary

Measure	Time frame
To aseess the improvement in Subjective parameters i.e. Signs and Symptoms of Amavata(Rheumatoid Arthritis)Timepoint: 30 days for each patient.	—

Secondary

Measure	Time frame
To aseess the improvement in Objective parameters i.e. Laboratory investigation, X-rays ect.Timepoint: 30 days for each patient.	—

Countries

India

Contacts

Public ContactDr Govind Kumar Verma

National Institute Of Ayurveda, Jaipur

harishbhakuni78@gmail.com7976128396

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026